Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 2Stage I Mixed Cell Type Kidney Wilms Tumor 1

Interventions

Carboplatin 129pembrolizumab 124Cisplatin 114Paclitaxel 102Gemcitabine 85Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 59Cyclophosphamide 59Pemetrexed 55Bevacizumab 54durvalumab 53Doxorubicin 52Radiotherapy 49Capecitabine 49Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 40Etoposide 38Letrozole 36atezolizumab 35Nivolumab 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Nephrectomy × 90 days × Clear all
NCT03055013 2026-06-03

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

National Cancer Institute (NCI)

Phase 3 Active not recruiting
819 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

NCT06401330 2026-05-05

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Oncology Group

Phase 3 Recruiting
1,656 enrolled
Genitourinary

Stage I Mixed Cell Type Kidney Wilms Tumor

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Sun Yat-sen University

Phase 3 Recruiting
298 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡